Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2+/− rat model
Hugo Ramos, Josy Augustine, Burak M. Karan, Cristina Hernández, Alan W. Stitt, Tim M. Curtis, Rafael Simó · 2024
Read Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2+/− rat model by Hugo Ramos, Josy Augustine, Burak M. Karan, Cristina Hernández, Alan W. Stitt, Tim M. Curtis, Rafael Simó (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11607821.txt.
Description
Hugo Ramos and six co-authors test sitagliptin eye drops in a new rat model of diabetic eye disease. Damage to the retinal neurovascular unit is an early event in diabetic retinopathy. The rat model lacks diabetes itself but shows like lesions, which makes it useful for isolating drug effects.
From three months of age, rats got sitagliptin or vehicle drops twice daily for two weeks. Treated model rats were compared with model and healthy control groups. Vehicle treated model rats showed retinal thinning, wider major vessels, inflammation and oxidation markers, glial activation, and dead capillaries. Sitagliptin drops prevented all of those changes, with no effect on body weight or blood sugar.
Catalog record
| CREATOR | Hugo Ramos, Josy Augustine, Burak M. Karan, Cristina Hernández, Alan W. Stitt, Tim M. Curtis, Rafael Simó |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |